About
Pipeline
For patients & physicians
Investors
Contact us
About
About BerGenBio
Management Team
Board of Directors
Scientific Advisory Board
Partners
Pipeline
Pipeline overview
BEMCENTINIB | NSCLC
BEMCENTINIB | SRI
TILVESTAMAB (BGB149)
Publications
For patients & physicians
Investors
Share Information and Policies
Share Data
Largest Shareholders
Stock Exchange Notices
Analyst Coverage
News
Financial Reports
Presentations
Financial Calendar
Corporate Governance
General Meetings
Environmental social and governance - ESG
Investor Relations
Rights Issue 2023
Contact us
Financial reports
2023
Close
Q2 2023 Report
Q1 2023 Report
Prospectus Rights issue 2023
2022
Open
Annual Report 2022
Q4 2022 Report
Q3 2022 Report
Q2 2022 Report
Q1 2022 Report
2021
Open
Annual Report 2021
Q4 and FY 2021 Report
Q3 2021 Report
Q2 2021 Report
Q1 2021 Report
2020
Open
Annual Report 2020
Q4 and FY 2020 Report
Q3 2020 Report
Q2 2020 Report
Prospectus 19 June 2020 BGBIO
Q1 2020 Report
Prospectus 26 February 2020 BGBIO
2019
Open
Annual Report 2019
Q4 and FY 2019 Report
Q3 2019 Report
Q2 2019 Report
Q1 2019 Report
2018
Open
Annual Report 2018
Q4 and FY 2018 Report
Q3 2018 Report
Q2 2018 Report
Q1 2018 Report
Prospectus regarding listing of shares under the Share Option Programme
2017
Open
Q4 and FY 2017 Report
Q3 2017 Report
Q2 2017 Report
Q1 2017 Report
Annual Report 2017
IPO prospectus
2016
Open
Annual Report 2016
2015
Open
Annual Report 2015